Sam Altman personally invests nearly $180 million in Retro Biosciences
Business
OpenAI's Sam Altman is betting big on the future of anti-aging, personally investing nearly $180 million in Retro Biosciences, a startup aiming to slow aging and fight diseases like Alzheimer's and cancer, using some cutting-edge science.
Retro is tackling aging by trying to "reset" aging cells back into a younger biological state and fight diseases like Alzheimer's and cancer, using some cutting-edge science.
Retro Biosciences uses OpenAI GPT-4b micro
Retro isn't just about biology: it's teaming up with OpenAI to use a special AI model called GPT-4b micro.
This tech helps design proteins faster and finds solutions scientists might miss on their own.
It says it's making real progress.